SCHEMBL20183622

SCHEMBL20183622

CCn1c(=O)cc(C2CC2)c2cc(NC(=O)c3ccc(C)cc3N)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.41
MEN1 O00255 9/20 0.41
KMT2A Q03164 9/20 0.41
POLB P06746 2/20 0.41
MAPK1 P28482 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGES O14684 1/20 0.40
KDM4E B2RXH2 5/20 0.40
HPGD P15428 3/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 5/20 0.39
HCRTR1 O43613 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20806146 0.80 TP53 (0.35) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL20183585 0.80 RORC (0.54) MAPTMEN1KMT2APOLBMAPK1
SCHEMBL21549489 0.79 KDM4E (0.43) MAPTMEN1KMT2APOLBKDM4E
SCHEMBL20183483 0.73 ALDH1A1 (0.49) MAPTMEN1KMT2AMAPK1TDP1
SCHEMBL20183746 0.72 KDM4E (0.42) MAPTMEN1KMT2AMAPK1KDM4E
SCHEMBL20183793 0.71 HSP90AA1 (0.36) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL20183593 0.71 BRD4 (0.43) MAPTMAPK1KDM4EHPGDALDH1A1
SCHEMBL20183518 0.71 BRD4 (0.39) MAPTMAPK1KDM4EHPGDALDH1A1
SCHEMBL20183580 0.70 PER2 (0.35) POLBKDM4EHPGDALDH1A1HTT
SCHEMBL20183755 0.70 NPY5R (0.34) MAPTPOLBMAPK1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 MAPT 3928/4885MEN1 1349/4885KMT2A 359/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 MAPT 4325/4885MEN1 524/4885KMT2A 3299/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 MAPT 3928/4885MEN1 1349/4885KMT2A 359/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 MAPT 4325/4885MEN1 524/4885KMT2A 3299/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 MAPT 4406/4885MEN1 953/4885KMT2A 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.